

Anti-ERBB2/HER2/CD340 Antibody (Trastuzumab-MMAE)

Introduction

Trastuzumab MMAE is an antibody-drug conjugate (ADC) consisting of the anti-HER2 antibody trastuzumab coupled to monomethyl auristatin E (MMAE) via a Mc linker. Trastuzumab MMAE has the potential to be used in solid tumor research, mainly HER2-positive breast cancer.

Product parameters

Alternative Names	trastuzumab-MMAE
Target Accession	P04626
Target	ERBB2 / HER2 / CD340
CAS number	/
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human HER2 His at 2 ug/mL can bind Anti-ERBB2 / HER2 / CD340 Reference Antibody (Trastuzumab-MMAE), EC50 is 0.008281 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

